Featured Testimonials
THOR on Facebook
THOR on Twitter
THOR on LinkedIn
THOR on Instagram
THOR on YouTubeTherese talks about how the NovoTHOR at Performance Bodywork in Portland, Oregon has been a huge help for her severe Rheumatoid Arthritis.
More NovoTHOR Testimonials | NovoTHOR Treatment Locations
View current Photobiomodulation therapy training dates in your location.
Ann Busby had lived most of her adult life in pain. Ann was diagnosed with fibromyalgia back in 2001. She has been using the NovoTHOR off and on for over a year and says the changes in her body have been incredible.
More NovoTHOR Testimonials | NovoTHOR Treatment Locations
View current Photobiomodulation therapy training dates in your location.
LumiThera Inc., a commercial stage medical device company creating a Photobiomodulation (PBM) treatment for ocular disorders and disease, today announced it is a recipient of a small business innovative research (SBIR) phase II grant from the National Institute of Health (NIH) and the division of the National Eye Institute (NEI).
The phase II grant supports a prospective, randomized, multi-center human clinical trial in U.S. subjects diagnosed with dry age-related macular degeneration (dry AMD.) The LIGHTSITE III trial, which is subject to FDA Investigational Device Exemption (IDE) approval, will test vision and examine disease pathology in the eye following PBM treatments using the Company’s Valeda™ Light Delivery System. Subjects will be followed for up to two years. In 2018, LumiThera obtained a CE mark to commercialize the Valeda™ Light Delivery System in Europe for the treatment of dry AMD. A companion post-marketing study (LIGHTSITE II) is being readied for Europe.
“Dry AMD is one of the largest unmet medical needs in medicine and its prevalence is increasing as we live longer,” commented Quan Dong Nguyen, M.D., M.Sc. and Diana V. Do, M.D., both professors of ophthalmology at the Byers Eye Institute, Stanford University School of Medicine. “In ophthalmology, currently, we have no therapies that can be offered to these patients. Both of us and many of our colleagues at Stanford, in the US, and throughout the world recognize the potential that PBM could provide as an early treatment for dry AMD, and if so, can bring significant benefits to millions of patients globally.”
“The LIGHTSITE II and III trials are part of LumiThera’s global efforts to bring forward a treatment for a debilitating eye disease that results in central loss of vision,” stated David Boyer, MD., Retina-Vitreous Associates Medical Group, Los Angeles, CA. “The planned European and US trials would create a novel treatment option for dry AMD patients, who currently have limited choices.”
“The NIH clinical grant is substantial in providing over $2.5M in funding to develop a PBM therapy for dry AMD patients in the U.S.,” stated Clark Tedford, Ph.D., President and CEO. “We are excited to have the NIH/NEI partially support the further development endeavors of LumiThera, and the grant is a significant step in the validation of the PBM technology and its potential in treating chronic eye disease.”
“We are very excited to be part of the LIGHTSITE U.S. multicenter trial.” remarked Richard Rosen, M.D., New York Eye and Ear Infirmary of Mount Sinai. “Several major U.S. centers are participating in this trial, which should help substantiate the clinical benefits of this therapy, reported to date. This trial will measure a variety of clinical and pathological outcomes and establish the long-term benefits of PBM for dry AMD patients.”
View the press release on Lumithera website at www.lumithera.com
Disclosure: I am an investor in Lumithera a) because it successfully treats an unmet medical need, (dry AMD) b) I think it will be the first billion dollar photobiomodulation company.
Lauren Irick used to be a professional bikini body builder and was taking 40 pills a day for chronic fatigue, brain fog, hormone imbalances and water retention before using NovoTHOR at Performance Bodywork, Portland, Oregon. Lauren talks about how NovoTHOR has helped her regain her health and is now back in the gym.
More NovoTHOR Testimonials | NovoTHOR Treatment Locations
View current Photobiomodulation therapy training dates in your location.
“Training in San Francisco met and exceeded my expectations. James covered so much and made it clearly understandable. He made it fun and engaging. I left feeling excited to share what I learned!
Can’t wait to buy your equipment! Mark and Sarah were full of knowledge too, funny and engaging!”
Aisling Scrosopp
Fitness/ Wellness
California, USA
View current Photobiomodulation therapy training dates in your location.
“I wanted to respond and reach out about how amazing the THOR class was in San Francisco. It was an all day class, but I honestly never wanted it to end. It was fun, interactive, and I learned a lot. All of the science and concepts behind this Laser/Light was very easy to comprehend. I feel like you summed up 4 years of my B.S. Degree in one day, which is AWESOME! It’s nice how you adapt the class to make sure everyone understands.
The handheld unit itself is also amazing. We are constantly treating people and the amount of a positive response that 100% of the people have is outstanding. Definitely interested in attending another class, just to keep up with what’s new with the technology. Well done!”
Christa Iams
Exercise Physiologist
Pittsburgh, USA
View current Photobiomodulation therapy training dates in your location.
Tony Robbins uses the NovoTHOR light bed and LX2 handheld to relieve muscle tightness quickly. Tony sat down with Mark Murdock, from CryoUSA, to discuss why it’s become such an integral strategy for recovery to help him stay in peak physical condition. He said the bed is fantastic which is why he has a couple in his homes and THOR LX2 Handheld ones for when travelling.
More NovoTHOR Testimonials | NovoTHOR Treatment Locations
View current Photobiomodulation therapy training dates in your location.
UK and Ireland dates
USA and Canada dates
Australia and NZ dates
Rest Of World dates